Patent · US Active

Crystalline forms of a MAGL inhibitor

US12152029B2 · kind B2 · utility

0Cited by
1References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 1, 2022
Grant dateNov 26, 2024
Priority date—
Expiry dateNov 1, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.